Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Source: SeekingAlpha
2026-01-08 22:34:48 ET
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia January 8, 2026 4:30 PM EST...
Read the full article on Seeking Alpha
For further details see:
Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript
Ascendis Pharma A/S
NASDAQ: ASND
ASND Trading
-1.73% G/L:
$225.31 Last:
283,518 Volume:
$230.76 Open:
ASND Latest News
March 02, 2026 08:43:00 am
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
February 27, 2026 05:57:16 pm
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
ASND Stock Data
$13,394,473,228
60,082,592
N/A
105
N/A
Biotechnology & Life Sciences
Healthcare
DK
Hellerup
